Hunan Hansen Pharmaceutical Co Ltd Net Assets
Hunan Hansen Pharmaceutical Co Ltd net assets. Based on the latest financial reports, Hunan Hansen Pharmaceutical Co Ltd (002412) has net assets worth CN¥2.42 Billion CNY (≈ $354.55 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.73 Billion ≈ $399.99 Million USD) and total liabilities (CN¥310.49 Million ≈ $45.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 002412 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.42 Billion |
| % of Total Assets | 88.64% |
| Annual Growth Rate | 20.65% |
| 5-Year Change | 36.65% |
| 10-Year Change | 89.19% |
| Growth Volatility | 87.7 |
Net Assets of Hunan Hansen Pharmaceutical Co Ltd (2006–2025)
Net assets of Hunan Hansen Pharmaceutical Co Ltd from 2006 to 2025. This chart illustrates how Hunan Hansen Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See Hunan Hansen Pharmaceutical Co Ltd (002412) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Hunan Hansen Pharmaceutical Co Ltd (2006–2025)
The table below shows the annual net assets of Hunan Hansen Pharmaceutical Co Ltd from 2006 to 2025. For live market cap and overall valuation, see 002412 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.38 Billion ≈ $348.40 Million |
+8.06% |
| 2024-12-31 | CN¥2.20 Billion ≈ $322.42 Million |
+12.24% |
| 2023-12-31 | CN¥1.96 Billion ≈ $287.25 Million |
+3.64% |
| 2022-12-31 | CN¥1.89 Billion ≈ $277.17 Million |
+8.71% |
| 2021-12-31 | CN¥1.74 Billion ≈ $254.95 Million |
+9.25% |
| 2020-12-31 | CN¥1.59 Billion ≈ $233.36 Million |
+4.23% |
| 2019-12-31 | CN¥1.53 Billion ≈ $223.88 Million |
+12.22% |
| 2018-12-31 | CN¥1.36 Billion ≈ $199.50 Million |
+11.82% |
| 2017-12-31 | CN¥1.22 Billion ≈ $178.41 Million |
-3.12% |
| 2016-12-31 | CN¥1.26 Billion ≈ $184.16 Million |
+0.40% |
| 2015-12-31 | CN¥1.25 Billion ≈ $183.42 Million |
+8.70% |
| 2014-12-31 | CN¥1.15 Billion ≈ $168.75 Million |
+4.11% |
| 2013-12-31 | CN¥1.11 Billion ≈ $162.08 Million |
+14.77% |
| 2012-12-31 | CN¥965.11 Million ≈ $141.23 Million |
+9.22% |
| 2011-12-31 | CN¥883.65 Million ≈ $129.31 Million |
-1.69% |
| 2010-12-31 | CN¥898.82 Million ≈ $131.53 Million |
+400.71% |
| 2009-12-31 | CN¥179.51 Million ≈ $26.27 Million |
+37.81% |
| 2008-12-31 | CN¥130.26 Million ≈ $19.06 Million |
+48.42% |
| 2007-12-31 | CN¥87.77 Million ≈ $12.84 Million |
+30.46% |
| 2006-12-31 | CN¥67.28 Million ≈ $9.84 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hunan Hansen Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3754.6% over the analyzed period, indicating profitable operations and earnings retention.
Hunan Hansen Pharmaceutical Co Ltd Net Assets Breakdown (December 2025)
Hunan Hansen Pharmaceutical Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.43 Billion | 60.09% |
| Other Components | CN¥950.14 Million | 39.91% |
| Total Equity | CN¥2.38 Billion | 100.00% |
Hunan Hansen Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Hunan Hansen Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Merry Electronics Co Ltd
TW:2439
|
$575.94 Million |
|
Saha Pathanapibul Public Company Limited
BK:SPC
|
$576.01 Million |
|
Atlanta Braves Holdings, Inc. Series A Common Stock
NASDAQ:BATRA
|
$576.17 Million |
|
G-Tech Optoelectronics Corp
TW:3149
|
$576.25 Million |
|
Shenzhen Kaizhong Precision Technology Co Ltd
SHE:002823
|
$575.65 Million |
|
BEIJ.JINGNENG CL.ERG.HYC1
F:BJ6
|
$575.62 Million |
|
Shenzhen Liande Automatic Equipment Co Ltd
SHE:300545
|
$575.61 Million |
|
Thai Stanley Electric Public Company Limited
BK:STANLY
|
$575.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hunan Hansen Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,203,382,060 to 2,380,923,605, a change of 177,541,545 (8.1%).
- Net income of 198,120,449 contributed positively to equity growth.
- Dividend payments of 1,725,347 reduced retained earnings.
- Other comprehensive income decreased equity by 222,876,857.
- Other factors increased equity by 204,023,300.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥198.12 Million | +8.32% |
| Dividends Paid | CN¥1.73 Million | -0.07% |
| Other Comprehensive Income | CN¥-222.88 Million | -9.36% |
| Other Changes | CN¥204.02 Million | +8.57% |
| Total Change | CN¥- | 8.06% |
Book Value vs Market Value Analysis
This analysis compares Hunan Hansen Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.65x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 56.88x to 1.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.14 | CN¥7.82 | x |
| 2007-12-31 | CN¥0.24 | CN¥7.82 | x |
| 2008-12-31 | CN¥0.35 | CN¥7.82 | x |
| 2009-12-31 | CN¥0.48 | CN¥7.82 | x |
| 2010-12-31 | CN¥2.00 | CN¥7.82 | x |
| 2011-12-31 | CN¥1.77 | CN¥7.82 | x |
| 2012-12-31 | CN¥1.92 | CN¥7.82 | x |
| 2013-12-31 | CN¥2.14 | CN¥7.82 | x |
| 2014-12-31 | CN¥2.23 | CN¥7.82 | x |
| 2015-12-31 | CN¥2.42 | CN¥7.82 | x |
| 2016-12-31 | CN¥2.50 | CN¥7.82 | x |
| 2017-12-31 | CN¥2.42 | CN¥7.82 | x |
| 2018-12-31 | CN¥2.71 | CN¥7.82 | x |
| 2019-12-31 | CN¥3.04 | CN¥7.82 | x |
| 2020-12-31 | CN¥3.17 | CN¥7.82 | x |
| 2021-12-31 | CN¥3.46 | CN¥7.82 | x |
| 2022-12-31 | CN¥3.76 | CN¥7.82 | x |
| 2023-12-31 | CN¥3.90 | CN¥7.82 | x |
| 2024-12-31 | CN¥4.38 | CN¥7.82 | x |
| 2025-12-31 | CN¥4.73 | CN¥7.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hunan Hansen Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.32%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.07%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.13x
- Recent ROE (8.32%) is below the historical average (13.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 21.39% | 8.87% | 0.60x | 4.03x | CN¥5.99 Million |
| 2007 | 43.15% | 22.69% | 0.96x | 1.99x | CN¥29.10 Million |
| 2008 | 32.62% | 18.03% | 1.10x | 1.65x | CN¥29.47 Million |
| 2009 | 27.44% | 17.39% | 1.15x | 1.38x | CN¥31.30 Million |
| 2010 | 6.90% | 18.06% | 0.36x | 1.05x | CN¥-27.86 Million |
| 2011 | 6.66% | 14.68% | 0.43x | 1.06x | CN¥-29.54 Million |
| 2012 | 8.44% | 16.64% | 0.47x | 1.08x | CN¥-15.05 Million |
| 2013 | 10.30% | 18.95% | 0.44x | 1.23x | CN¥3.24 Million |
| 2014 | 10.49% | 15.95% | 0.54x | 1.22x | CN¥5.49 Million |
| 2015 | 8.04% | 12.56% | 0.57x | 1.13x | CN¥-23.94 Million |
| 2016 | 6.75% | 10.64% | 0.48x | 1.33x | CN¥-40.90 Million |
| 2017 | 8.92% | 13.11% | 0.49x | 1.39x | CN¥-13.12 Million |
| 2018 | 10.82% | 16.00% | 0.51x | 1.32x | CN¥11.20 Million |
| 2019 | 10.61% | 18.30% | 0.47x | 1.23x | CN¥9.38 Million |
| 2020 | 6.66% | 14.32% | 0.39x | 1.18x | CN¥-53.33 Million |
| 2021 | 7.74% | 15.12% | 0.42x | 1.21x | CN¥-39.38 Million |
| 2022 | 8.85% | 18.30% | 0.40x | 1.21x | CN¥-21.80 Million |
| 2023 | 10.44% | 21.46% | 0.41x | 1.19x | CN¥8.71 Million |
| 2024 | 10.00% | 21.93% | 0.39x | 1.16x | CN¥-93.79K |
| 2025 | 8.32% | 19.07% | 0.39x | 1.13x | CN¥-39.97 Million |
Industry Comparison
This section compares Hunan Hansen Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,124,889,896
- Average return on equity (ROE) among peers: 7.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hunan Hansen Pharmaceutical Co Ltd (002412) | CN¥2.42 Billion | 21.39% | 0.13x | $575.82 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $902.62 Million | 5.17% | 3.60x | $492.82 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.56 Billion | 7.90% | 1.45x | $363.79 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $366.91 Million | 9.97% | 0.26x | $4.71 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $14.91 Billion | 13.83% | 0.64x | $2.63 Billion |
| Wedge Industrial Co Ltd (000534) | $654.70 Million | 1.92% | 0.87x | $1.28 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $14.36 Billion |
| Hainan Haiyao Co Ltd (000566) | $317.39 Million | 7.74% | 0.74x | $766.98 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $268.54 Million | 1.60% | 1.47x | $273.68 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $889.22 Million | 5.34% | 2.43x | $935.44 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.35 Billion | 7.34% | 0.44x | $3.04 Billion |
About Hunan Hansen Pharmaceutical Co Ltd
Hunan Hansen Pharmaceutical Co., Ltd. engages in the production and sale of traditional Chinese preparations in China and internationally. The company offers medications for digestive, cardiovascular, cerebrovascular, and urological diseases, as well as for traumatology and diagnostic applications. It provides its products in various forms, including injections, mixtures, tablets, capsules, granu… Read more